A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs CUDC 907 (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 20 Jan 2017 Planned primary completion date changed from 1 Sep 2024 to 30 Sep 2024.
- 30 Dec 2016 Status changed from not yet recruiting to recruiting.
- 29 Dec 2016 New trial record